Evidence map›Paper›PMID 28163218›Full record

ArticleJournal of chemical neuroanatomy2017

Atypical dopamine efflux caused by 3,4-methylenedioxypyrovalerone (MDPV) via the human dopamine transporter.

Aparna Shekar, Jenny I Aguilar, Greta Galli, Nicholas V Cozzi, Simon D Brandt, Arnold E Ruoho, Michael H Baumann, Heinrich J G Matthies, Aurelio Galli

Abstract read
In one paragraph

Article in Journal of chemical neuroanatomy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Neuropharmacology of Synthetic Cathinones.Handbook of experimental pharmacology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aparna ShekarDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232-8548, United States; Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37232-8548, United States; Neuroscience Program in Substance Abuse (N-PISA), Vanderbilt University, Nashville, TN 37232-8548, United States.
Jenny I AguilarDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232-8548, United States; Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37232-8548, United States; Neuroscience Program in Substance Abuse (N-PISA), Vanderbilt University, Nashville, TN 37232-8548, United States.
Greta GalliUniversity School of Nashville, Nashville, TN 37212, United States.
Nicholas V CozziNeuropharmacology Laboratory, Department of Cell and Regenerative Biology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706, United States.
Simon D BrandtSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK.
Arnold E RuohoDepartment of Neuroscience, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, United States.
Michael H BaumannDesigner Drug Research Unit (DDRU), Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, United States.
Heinrich J G MatthiesVanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37232-8548, United States; Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN 37232-8548, United States.
Aurelio GalliVanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37232-8548, United States; Neuroscience Program in Substance Abuse (N-PISA), Vanderbilt University, Nashville, TN 37232-8548, United States; Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN 37232-8548, United States. Electronic address: aurelio.galli@vanderbilt.edu.

Funding

Studies on MDMA and Related CompoundsZIADA000523 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI BAUMANN, MICHAEL · 2009 to 2025
$16.4M
TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007628 · NIGMS · VANDERBILT UNIVERSITY · PI BARNETT, JOEY VICTOR, KAVALALI, EGE T · 1985 to 2022
$11.2M
Vanderbilt/Meharry Initiative for Minority Student DvptR25GM062459 · NIGMS · VANDERBILT UNIVERSITY · PI VELEZ EDWARDS, DIGNA R · 2002 to 2020
$10.4M
Preclinical medication development for stimulant use disorderZIADA000522 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI BAUMANN, MICHAEL · 2009 to 2025
$8.9M
The Role of the Dopamine Transporter in Psychostimulant AbuseR01DA038058 · NIDA · VANDERBILT UNIVERSITY · PI GALLI, AURELIO, MATTHIES, HEINRICH J.G. · 2014 to 2025
$4.6M
The dopamine transporter's lipid interactions: understanding transporter functionR01DA035263 · NIDA · VANDERBILT UNIVERSITY · PI GALLI, AURELIO, MATTHIES, HEINRICH J.G. · 2014 to 2023
$3.8M
Altered Dopamine Transporter Function in AutismF31MH114316 · NIMH · VANDERBILT UNIVERSITY · PI AGUILAR, JENNY ISABEL · 2017 to 2019
$88k
Intramural NIH HHS ZIA DA000523NIDA NIH HHS R01 DA035263NIDA NIH HHS R01 DA038058NIGMS NIH HHS R25 GM062459NIGMS NIH HHS T32 GM007628NIMH NIH HHS F31 MH114316
6 · The paper itself

Abstract

Synthetic cathinones are similar in chemical structure to amphetamines, and their behavioral effects are associated with enhanced dopaminergic signaling. The past ten years of research on the common constituent of bath salts, MDPV (the synthetic cathinone 3,4-methylenedioxypyrovalerone), has aided the understanding of how synthetic cathinones act at the dopamine (DA) transporter (DAT). Several groups have described the ability of MDPV to block the DAT with high-affinity. In this study, we demonstrate for the first time a new mode of action of MDPV, namely its ability to promote DAT-mediated DA efflux. Using single cell amperometric assays, we determined that low concentrations of MDPV (1nM) can cause reverse transport of DA via DAT. Notably, administration of MDPV leads to hyperlocomotion in Drosophila melanogaster. These data describe further how MDPV acts at the DAT, possibly paving the way for novel treatment strategies for individuals who abuse bath salts.

Indexed as

AnimalsBenzodioxolesDopamineDopamine Plasma Membrane Transport ProteinsDrosophila melanogasterHumansPsychotropic DrugsPyrrolidinesSynthetic CathinoneBenzodioxolesDopamineDopamine Plasma Membrane Transport ProteinsPsychotropic DrugsPyrrolidinesSynthetic Cathinone3,4-methylenedioxypyrovaleroneAmphetamineDopamine transporterDrosophila

Identifiers

PMID28163218
PMCPMC5540822

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.